NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.53 per share when it actually produced a loss of $0.45, delivering a surprise of 15.09%.Over the last four quarters, the company has ...